Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland

References

• Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Chen J, Brady P. Gastroesophageal reflux disease: pathophysiology, diagnosis, and treatment. Gastroenterol Nurs. 2019;42(1):20–28. doi: 10.1097/SGA.0000000000000359.
   PubMed Web of Science ®Google Scholar
• Choi KKH, Sanagapalli S. Barrett’s esophagus: review of natural history and comparative efficacy of endoscopic and surgical therapies. World J Gastrointest Oncol. 2022;14(3):568–586. doi: 10.4251/wjgo.v14.i3.568.
   PubMed Web of Science ®Google Scholar
• Nirwan JS, Hasan SS, Babar ZU, et al. Global prevalence and risk factors of Gastro-oesophageal Reflux Disease (GORD): Systematic review with meta-analysis. Sci Rep. 2020;10(1):5814. doi: 10.1038/s41598-020-62795-1.
   PubMed Web of Science ®Google Scholar
• Lenoir C, El Biali M, Luthy C, et al. Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more? Int J Clin Pharm. 2019;41(6):1634–1641. doi: 10.1007/s11096-019-00929-w.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Clinical guideline [CG184]: gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. London (UK): ational Institute for Health and Care Excellence (NICE); 2019.
   Google Scholar
• Delshad SD, Almario CV, Chey WD, et al. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158(5):1250–1261.e2. doi: 10.1053/j.gastro.2019.12.014.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence: Guidelines. Interventional procedures guidance [IPG749]: laparoscopic insertion of a magnetic ring for gastroesophageal reflux disease. London (UK): National Institute for Health and Care Excellence (NICE); 2023.
   Google Scholar
• Bonavina L, Horbach T, Schoppmann SF, et al. Three-year clinical experience with magnetic sphincter augmentation and laparoscopic fundoplication. Surg Endosc. 2021;35(7):3449–3458. doi: 10.1007/s00464-020-07792-1.
   PubMed Web of Science ®Google Scholar
• Skubleny D, Switzer NJ, Dang J, et al. LINX(®) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078–3084. doi: 10.1007/s00464-016-5370-3.
   PubMed Web of Science ®Google Scholar
• Bjelović M, Harsányi L, Altorjay Á, et al. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results: RefluxStop™ device; a new method in acid reflux surgery obtaining CE mark. BMC Surg. 2020;20(1):159. doi: 10.1186/s12893-020-00794-9.
   PubMed Web of Science ®Google Scholar
• Barbier M, Durno N, Bennison C, et al. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. Eur J Health Econ. 2022;23(5):837–846. doi: 10.1007/s10198-021-01398-7.
   PubMed Web of Science ®Google Scholar
• Panje CM, Lupatsch JE, Barbier M, et al. A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol. 2020;31(4):501–506. doi: 10.1016/j.annonc.2020.01.007.
   PubMed Web of Science ®Google Scholar
• Harper S, Grodzicki L, Mealing S, et al. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease. J Med Econ. 2023;26(1):603–613. doi: 10.1080/13696998.2023.2201063.
   PubMed Web of Science ®Google Scholar
• Grant A, Wileman S, Ramsay C, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease – a UK collaborative study. The REFLUX trial. Health Technol Assess. 2008;12(31):1–181, iii–iv. doi: 10.3310/hta12310.
   PubMed Web of Science ®Google Scholar
• Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513–1523. doi: 10.1056/NEJMoa1811424.
   PubMed Web of Science ®Google Scholar
• Bojke L, Hornby E, Sculpher M, REFLUX Trial Team. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics. 2007;25(10):829–841. doi: 10.2165/00019053-200725100-00003.
   PubMed Web of Science ®Google Scholar
• Karolinska Institute. Literature review and analysis: laparoscopic Nissen fundoplication. [Unpublished]. 2017 (Version KILNF001).
   Google Scholar
• Implantica. RefluxStop CE Mark Trial – 3-year data; 2022 Data on file. [Unpublished but currently in peer-review].
   Google Scholar
• Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED) for LINX reflux management system; 2012 [cited 2023 Apr 6]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100049b.pdf.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Dyspepsia and gastro-oesophageal reflux disease. Appendix H: Full Health Economics Report; 2014. https://www.nice.org.uk/guidance/cg184/evidence/appendix-h-full-health-economics-report-pdf-6955335252
   Google Scholar
• WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332–e1345.
   PubMed Web of Science ®Google Scholar
• Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443–450. doi: 10.1016/j.hlc.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Collins G, Altman D. Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney® scores using a primary care database. Br J Gen Pract. 2012;62(597):e243–e250. doi: 10.3399/bjgp12X636065.
   PubMed Web of Science ®Google Scholar
• Hussain S, Singh A, Habib A, et al. Proton pump inhibitors use and risk of chronic kidney disease: evidence-based meta-analysis of observational studies. Clin Epidemiol Global Health. 2019;7(1):46–52. doi: 10.1016/j.cegh.2017.12.008.
   Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397. doi: 10.1007/s00198-007-0543-5.
   PubMed Web of Science ®Google Scholar
• Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–347. doi: 10.1007/s00198-015-3365-x.
   PubMed Web of Science ®Google Scholar
• Sun X, Douiri A, Gulliford M. Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study. Epidemiol Infect. 2019;147:e263. doi: 10.1017/S0950268819001559.
   PubMed Web of Science ®Google Scholar
• Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004. doi: 10.1371/journal.pone.0128004.
   PubMed Web of Science ®Google Scholar
• Public Health England. Clostridium difficile infection: mandatory surveillance 2017/18; 2018. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/724368/CDI_summary_2018.pdf
   Google Scholar
• Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–1010. doi: 10.1038/ajg.2012.179.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739. doi: 10.1136/bmjopen-2017-017739.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Interventional procedures guidance [IPG585]: laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease; 2017. Available from: https://www.nice.org.uk/guidance/ipg585
   Google Scholar
• Alicuben ET, Bell RCW, Jobe BA, et al. Worldwide experience with erosion of the magnetic sphincter augmentation device. J Gastrointest Surg. 2018;22(8):1442–1447. doi: 10.1007/s11605-018-3775-0.
   PubMed Web of Science ®Google Scholar
• Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (Netherlands): Springer; 2014.
   Google Scholar
• Ainslie WG, Catton JA, Davides D, et al. Micropuncture cholecystectomy vs conventional laparoscopic cholecystectomy: a randomized controlled trial. Surg Endosc. 2003;17(5):766–772. doi: 10.1007/s00464-002-8568-5.
   PubMed Web of Science ®Google Scholar
• Bouvy JC, Ebbers HC, Schellekens H, et al. The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther. 2013;93(5):433–442. doi: 10.1038/clpt.2013.13.
   PubMed Web of Science ®Google Scholar
• Ayazi S, Zheng P, Zaidi AH, et al. Magnetic Sphincter augmentation and postoperative dysphagia: characterization, clinical risk factors, and management. J Gastrointest Surg. 2020;24(1):39–49. doi: 10.1007/s11605-019-04331-9.
   PubMed Web of Science ®Google Scholar
• Tsai C, Steffen R, Kessler U, et al. Postoperative dysphagia following magnetic sphincter augmentation for gastroesophageal reflux disease. Surg Laparosc Endosc Percutan Tech. 2020;30(4):322–326. doi: 10.1097/SLE.0000000000000785.
   PubMed Web of Science ®Google Scholar
• Pollit V, Graham D, Leonard C, et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett’s oesophagus in the United Kingdom. Curr Med Res Opin. 2019;35(5):805–815.
   PubMed Web of Science ®Google Scholar
• Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500–6515. doi: 10.3748/wjg.v23.i35.6500.
   PubMed Web of Science ®Google Scholar
• Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018;25(3):141–151. doi: 10.11005/jbm.2018.25.3.141.
   PubMedGoogle Scholar
• Poly TN, Lin MC, Syed-Abdul S, et al. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel). 2022;14(13):3052. doi: 10.3390/cancers14133052.
   Web of Science ®Google Scholar
• Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–342. doi: 10.1093/ndt/gfw470.
   PubMed Web of Science ®Google Scholar
• Nguyen PA, Islam M, Galvin CJ, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020;32(5):292–299. doi: 10.1093/intqhc/mzaa041.
   PubMed Web of Science ®Google Scholar
• Batchelor R, Kumar R, Gilmartin-Thomas JFM, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780–796. doi: 10.1111/apt.14955.
   PubMed Web of Science ®Google Scholar
• Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237–249. doi: 10.1093/aje/kwn121.
   PubMed Web of Science ®Google Scholar
• Swiss DRG. [cited 2023 Apr 6]. Available from: https://www.swissdrg.org/de/grouper/grouper/online-grouper.
   Google Scholar
• Jones K, Burns A. Unit costs of health and social care 2021. Kent (UK): Personal Social Services Research Unit (PSSRU); 2021.
   Google Scholar
• Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy J Res Debate Pract. 2010;6(1):51–59. doi: 10.1332/174426410X482999.
   Google Scholar
• Swiss Federal Office. Spezialitätenliste. [Available from: https://www.spezialitaetenliste.ch/ShowPreparations.aspx.
   Google Scholar
• Buyukkaramikli N, Abraham K, Vroling H, et al. Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitors. 2020 [cited 2023 May 10]. Available from: https://www.bag.admin.ch/dam/bag/en/dokumente/kuv-leistungen/leistungen-und-tarife/hta/berichte/h0025ppir-hta-report.pdf.download.pdf/h0025ppir-hta-report.pdf.
   Google Scholar
• Palser TR, Ceney A, Navarro A, et al. Variation in laparoscopic anti-reflux surgery across England: a 5-year review. Surg Endosc. 2018;32(7):3208–3214. doi: 10.1007/s00464-018-6038-y.
   PubMed Web of Science ®Google Scholar
• Kerr M, Bray B, Medcalf J, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27 Suppl 3(Suppl 3):iii73–iii80. doi: 10.1093/ndt/gfs269.
   PubMedGoogle Scholar
• Gandjour A, Kleinschmit F, Lauterbach KW, INTERCARE International Investigators. International Comparison of Costs and Quality in Health Care. European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001). Eur Heart J. 2002;23(11):858–868. doi: 10.1053/euhj.2001.3080.
   PubMed Web of Science ®Google Scholar
• Blach S, Schaetti C, Bruggmann P, et al. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Med Wkly. 2019;149:w20026. doi: 10.4414/smw.2019.20026.
   PubMed Web of Science ®Google Scholar
• Fischer B, Serra A, Telser H. Cost-effectiveness of treating patients with chronic kidney disease and prior hyperkalemia with renin-angiotensin-aldosterone system inhibitor and patiromer: a Swiss public healthcare perspective. Adv Ther. 2022;39(6):2717–2730. doi: 10.1007/s12325-022-02123-3.
   PubMed Web of Science ®Google Scholar
• Sandoz MS, Ess SM, Keusch GW, et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly. 2004;134(31-32):448–458. doi: 10.4414/smw.2004.10682.
   PubMed Web of Science ®Google Scholar
• Kidneyfailurerisk.com. The kidney failure risk equation. [cited 2023 Apr 6]. Available from: https://kidneyfailurerisk.com/.
   Google Scholar
• Wieser S, Rüthemann I, De Boni S, et al. Cost of acute coronary syndrome in Switzerland in 2008. Swiss Med Wkly. 2012;142:w13655. doi: 10.4414/smw.2012.13655.
   PubMed Web of Science ®Google Scholar
• Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(1):137. doi: 10.1007/s11657-013-0137-0.
   PubMed Web of Science ®Google Scholar
• Keitel K, Alcoba G, Lacroix L, et al. Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland. Swiss Med Wkly. 2014;144:w13925. doi: 10.4414/smw.2014.13925.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Quality standard [QS110]: pneumonia in adults; 2016. Available from: https://www.nice.org.uk/guidance/qs110
   Google Scholar
• Pillai N, Dusheiko M, Maillard MH, et al. The evolution of health care utilisation and costs for inflammatory bowel disease over ten years. J Crohns Colitis. 2019;13(6):744–754. doi: 10.1093/ecco-jcc/jjz003.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA378]: Remucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. 2016. Available from: https://www.nice.org.uk/guidance/ta378
   Google Scholar
• Laudicella M, Walsh B, Munasinghe A, et al. Impact of laparoscopic versus open surgery on hospital costs for colon cancer: a population-based retrospective cohort study. BMJ Open. 2016;6(11):e012977. doi: 10.1136/bmjopen-2016-012977.
   PubMed Web of Science ®Google Scholar
• Manzo CA, Asti E, Bonavina L. Hiatal hernia, lower esophageal sphincter and their combined effect on the natural history of gastroesophageal reflux disease: implications for surgical therapy. Ann Laparosc Endosc Surg. 2021;6:44–44. doi: 10.21037/ales-20-26.
   Web of Science ®Google Scholar
• Rettura F, Bronzini F, Campigotto M, et al. Refractory gastroesophageal reflux disease: a management update. Front Med (Lausanne). 2021;8:765061. doi: 10.3389/fmed.2021.765061.
   PubMed Web of Science ®Google Scholar
• Schwenkglenks M, Marbet UA, Szucs TD. Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study. Soz Praventivmed. 2004;49(1):51–61. doi: 10.1007/s00038-003-2090-y.
   PubMedGoogle Scholar
• The Royal College of Surgeons of England. From innovation to adoption. Successfully spreading surgical innovation; 2014. Available from: https://www.rcseng.ac.uk/-/media/files/rcs/library-and-publications/non-journal-publications/rcs_innovation_to_adoption_2014_web-(1).pdf
   Google Scholar
• McCulloch P, Taylor I, Sasako M, et al. Randomised trials in surgery: problems and possible solutions. BMJ. 2002;324(7351):1448–1451. doi: 10.1136/bmj.324.7351.1448.
   PubMed Web of Science ®Google Scholar